Split History
ETFs Holding CBIO »    CBIO Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Catalyst Biosciences is a clinical-stage biotechnology company. Co. focuses in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration. Co.'s advanced program is a coagulation Factor VIIa variant, CB 813d, for treatment of severe hemophilia A and B patients. Co. has two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, which a Factor IX drug for the prophylactic treatment of patients with hemophilia B, a disease caused by a genetic deficiency in coagulation Factor IX; and a Factor Xa variant. According to our CBIO split history records, Catalyst Biosciences has had 1 split.
CBIO split history picture
Catalyst Biosciences (CBIO) has 1 split in our CBIO split history database. The split for CBIO took place on August 21, 2015. This was a 1 for 7 reverse split, meaning for each 7 shares of CBIO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split.

When a company such as Catalyst Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the CBIO split history from start to finish, an original position size of 1000 shares would have turned into 142.857142857143 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Catalyst Biosciences shares, starting with a $10,000 purchase of CBIO, presented on a split-history-adjusted basis factoring in the complete CBIO split history. CBIO split adjusted history picture

Growth of $10,000.00
With Dividends Reinvested

Start date: 01/22/2007
End date: 01/20/2017
Start price/share: $62.30
End price/share: $0.59
Starting shares: 160.51
Ending shares: 255.65
Dividends reinvested/share: $3.98
Total return: -98.49%
Average Annual Total Return: -34.25%
Starting investment: $10,000.00
Ending investment: $150.82
Years: 10.00
 
Growth of $10,000.00
Without Dividends Reinvested

Start date: 01/22/2007
End date: 01/20/2017
Start price/share: $62.30
End price/share: $0.59
Dividends collected/share: $3.98
Total return: -92.66%
Average Annual Total Return: -22.98%
Starting investment: $10,000.00
Ending investment: $734.05
Years: 10.00
Date Ratio
08/21/20151 for 7
CBIO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CBLI Split History
CBM Split History
CBMX Split History
CBRX Split History
CCM Split History
CDXC Split History
CELG Split History
CERE Split History
CGC Split History
CGNT Split History

DryShips Inc. (DRYS)
WisdomTree SmallCap Earnings Fund (EES)
WisdomTree MidCap Earnings Fund (EZM)
RGC Resources, Inc. (RGCO)
Sunshine Heart, Inc. (SSH)
Neuralstem, Inc. (CUR)
Gevo, Inc. (GEVO)
Interpace Diagnostics Group, Inc. (IDXG)
EnteroMedics Inc. (ETRM)
First Foundation Inc. (FFWM)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CBIO Insider Buying

CBIO Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.